Shares of Shire PLC (NASDAQ:SHPG) gapped up prior to trading on Monday . The stock had previously closed at $187.15, but opened at $188.50. Shire PLC shares last traded at $192.37, with a volume of 1,344,800 shares.

A number of research firms have issued reports on SHPG. Shore Capital reaffirmed a “buy” rating on shares of Shire PLC in a research note on Tuesday, August 30th. Jefferies Group reissued a “buy” rating on shares of Shire PLC in a research report on Wednesday, August 17th. TheStreet downgraded Shire PLC to a “hold” rating in a research report on Thursday, August 4th. Zacks Investment Research raised Shire PLC from a “sell” rating to a “hold” rating in a research report on Thursday, August 4th. Finally, RBC Capital Markets reissued an “outperform” rating on shares of Shire PLC in a research report on Wednesday, August 3rd. Four analysts have rated the stock with a hold rating and twenty-four have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $237.41.

The firm has a market cap of $57.30 billion and a P/E ratio of 39.98. The stock’s 50-day moving average is $195.29 and its 200 day moving average is $180.79.

Shire PLC (NASDAQ:SHPG) last posted its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.35. The business had revenue of $2.43 million for the quarter, compared to analyst estimates of $2.28 billion. During the same period last year, the business earned $2.63 EPS. Shire PLC’s revenue was up 55.9% compared to the same quarter last year. On average, equities research analysts predict that Shire PLC will post $12.93 earnings per share for the current fiscal year.

The firm also recently announced a dividend, which will be paid on Friday, October 7th. Shareholders of record on Friday, September 9th will be paid a dividend of $0.139 per share. The ex-dividend date of this dividend is Wednesday, September 7th.

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.